The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.
about
Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F.The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distributionCentromere protein F includes two sites that couple efficiently to depolymerizing microtubulesProtein farnesyltransferase and protein prenylation in Plasmodium falciparumPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerA yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimeticsZebrafish lipid metabolism: from mediating early patterning to the metabolism of dietary fat and cholesterol.Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defectA novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochoresInhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsTargeting protein prenylation for cancer therapyTargeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.Farnesyltransferase inhibitors: mechanism and applications.Lipid posttranslational modifications. Farnesyl transferase inhibitors.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Inhibition of farnesyltransferase: a rational approach to treat cancer?Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancerPhase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.Mechanisms of Chromosome Congression during Mitosis.Mitosis as an anti-cancer drug target.Cdc20 is required for the post-anaphase, KEN-dependent degradation of centromere protein F.The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.CAAX-box protein, prenylation process and carcinogenesis.High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
P2860
Q24292895-EACEA310-5FA0-48FA-91A1-0390DEE1C342Q24805139-C1A268E3-7033-48E3-97F9-D13CE0BB2B81Q27310847-B344993E-4041-4CE6-B2B2-9FBC8AA7F312Q27973925-2DACC154-F30A-4418-95D6-A7E67A628F61Q28240692-62D520FC-663C-407E-BC1A-EDBB4CB7D5EAQ28382899-DF6C32A8-C42C-4ED5-85D0-F7BE713DA8E7Q30402413-65163C15-8DDE-49DF-BD70-4D429544734AQ30499125-C6267AD2-20F2-4883-9051-E810FE07ECC9Q30635394-CEEF49EB-1A6D-442C-B3B8-5E5F65B613C3Q31115129-CEA4A514-6A3B-4E3A-BC41-D02B37CF0878Q33343716-20369528-2BAB-44B6-AB67-5354178AC9A9Q33669995-BEDAC87B-2B40-48B5-BA1C-AB0430DCDD53Q33679239-BA5456FF-E18D-4090-8132-BCF60D89953DQ33779007-C4A55442-B4FC-4BFD-8223-08A622FF9B5CQ34481874-7BC5DBBD-94F5-4F36-BB8F-393D1E3CFE4DQ34651253-5DD23A1E-E975-4118-9D71-302422B94392Q34659415-08FFDD08-64AF-4097-83AC-746ACBB645AEQ35091519-065D193A-F0EC-4DC6-8ED9-3C2482D0F264Q35166852-61F710CD-5561-4F47-9B87-54F39D78DE9EQ35186888-252242CA-D55D-4A4B-9D2A-4DA549F3C16DQ35621957-7D052630-9955-4377-83A8-4EF30F2A599DQ35634151-C9DBC8DB-1CCC-4D50-8524-7C90CDD026A7Q35774565-248930C8-FF41-42DB-A03D-1B61F0DD6A0AQ36429603-52BF8175-7126-466A-87A2-75CF364D2E1EQ36828655-5EFD99B9-EE1D-453A-AA29-6CC62F462ACFQ36946766-15DA23E5-034F-4FD5-869D-B9C1FB12A29AQ37137960-75932A24-88AB-4914-B5C8-CCB1585545F4Q37149363-D66D35C7-4305-44A8-A51B-C8EB5F3B4EADQ37723277-0B48EE02-6847-466C-B9EA-402B40B07F02Q37728193-DDF1C7A2-3456-46DE-8CA2-3A6B9633F2F8Q38115166-A6A13EFC-FF53-4E1B-B5EA-24CEA89E4547Q39755325-00EA0222-3798-4AC0-B44F-D0F4914B121CQ39762559-9BCF50C8-41DB-426F-9B42-870BEF0F2D7EQ40726065-63FF6E8C-DAEE-436F-A3EC-E8FA90E599E9Q41134538-B6A97AA2-5708-4A61-9036-EA40EAED13E1Q42069148-5CE4D380-7B40-4DDD-B9B4-8F1AE175F8FBQ42798921-929B31DB-C18C-4F11-88E4-C5D298B59314Q44645852-0B70E8EF-4876-4949-865C-31AF988E1643Q54478541-962059B8-ECEB-42B5-8976-C1B07AE82200
P2860
The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The farnesyltransferase inhibi ...... is of human lung cancer cells.
@ast
The farnesyltransferase inhibi ...... is of human lung cancer cells.
@en
type
label
The farnesyltransferase inhibi ...... is of human lung cancer cells.
@ast
The farnesyltransferase inhibi ...... is of human lung cancer cells.
@en
prefLabel
The farnesyltransferase inhibi ...... is of human lung cancer cells.
@ast
The farnesyltransferase inhibi ...... is of human lung cancer cells.
@en
P2093
P2860
P356
P1476
The farnesyltransferase inhibi ...... sis of human lung cancer cells
@en
P2093
P2860
P304
16161-16167
P356
10.1074/JBC.M006213200
P407
P577
2001-01-11T00:00:00Z